- Home
- ENTA vs CRML Comparison
ENTA vs CRML Comparison
Compare ENTA & CRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CRML
- Stock Information
- Founded
- ENTA 1995
- CRML N/A
- Country
- ENTA United States
- CRML United States
- Employees
- ENTA N/A
- CRML N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CRML
- Sector
- ENTA Health Care
- CRML
- Exchange
- ENTA Nasdaq
- CRML NYSE
- Market Cap
- ENTA 154.0M
- CRML 146.8M
- IPO Year
- ENTA 2013
- CRML N/A
- Fundamental
- Price
- ENTA $5.10
- CRML $2.49
- Analyst Decision
- ENTA Buy
- CRML
- Analyst Count
- ENTA 4
- CRML 0
- Target Price
- ENTA $17.25
- CRML N/A
- AVG Volume (30 Days)
- ENTA 266.6K
- CRML 2.1M
- Earning Date
- ENTA 05-05-2025
- CRML 02-01-2025
- Dividend Yield
- ENTA N/A
- CRML N/A
- EPS Growth
- ENTA N/A
- CRML N/A
- EPS
- ENTA N/A
- CRML N/A
- Revenue
- ENTA $66,590,999.00
- CRML $476,979.00
- Revenue This Year
- ENTA N/A
- CRML N/A
- Revenue Next Year
- ENTA N/A
- CRML N/A
- P/E Ratio
- ENTA N/A
- CRML N/A
- Revenue Growth
- ENTA N/A
- CRML 326.80
- 52 Week Low
- ENTA $4.09
- CRML $1.23
- 52 Week High
- ENTA $17.24
- CRML $12.49
- Technical
- Relative Strength Index (RSI)
- ENTA 43.45
- CRML 57.86
- Support Level
- ENTA $4.55
- CRML $2.04
- Resistance Level
- ENTA $5.29
- CRML $2.81
- Average True Range (ATR)
- ENTA 0.47
- CRML 0.39
- MACD
- ENTA 0.06
- CRML 0.20
- Stochastic Oscillator
- ENTA 63.96
- CRML 79.70
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.